Cargando…

Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group

In the present review, we briefly discuss the breakthrough advances in precision medicine using a tumor-agnostic approach and focus on BRAF treatment modalities, the mechanisms of resistance and the diagnostic approach in cancers with BRAF mutations. Tumor-type agnostic drug therapies work across ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vranic, Semir, Basu, Gargi D., Hall, David W., Gatalica, Zoran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Sciences and Arts of Bosnia and Herzegovina 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116180/ https://www.ncbi.nlm.nih.gov/pubmed/36799315 http://dx.doi.org/10.5644/ama2006-124.392

Ejemplares similares

Targeting HER2 expression in cancer: New drugs and new indications
por: Vranić, Semir, et al.
Publicado: (2021)

Trop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers
por: Vranic, Semir, et al.
Publicado: (2022)

Assay‐agnostic spatial profiling detects tumor microenvironment signatures: new diagnostic insights for triple‐negative breast cancer
por: Ziegler, Colleen, et al.
Publicado: (2023)

Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: Analysis of 1806 cases
por: Gatalica, Zoran, et al.
Publicado: (2014)

PD-L1 testing by immunohistochemistry in immuno-oncology
por: Vranic, Semir, et al.
Publicado: (2023)

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
por: Adashek, Jacob J., et al.
Publicado: (2022)

Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature
por: Bernocchi, Ottavia, et al.
Publicado: (2021)

Biomarkers of Targeted Therapy and Immuno-Oncology in Cancers Metastatic to the Breast
por: Vranic, Semir, et al.
Publicado: (2020)

NUTM1-Rearranged Neoplasms—A Heterogeneous Group of Primitive Tumors with Expanding Spectrum of Histology and Molecular Alterations—An Updated Review
por: Luo, Wenyi, et al.
Publicado: (2021)

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy
por: Gouda, M.A., et al.
Publicado: (2023)

An Updated Review of the Biomarkers of Response to Immune Checkpoint Inhibitors in Merkel Cell Carcinoma: Merkel Cell Carcinoma and Immunotherapy
por: Fojnica, Adnan, et al.
Publicado: (2023)

Molecular Profiling Reveals Limited Targetable Biomarkers in Neuroendocrine Carcinoma of the Cervix
por: Cimic, Adela, et al.
Publicado: (2021)

High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine
por: Gatalica, Zoran, et al.
Publicado: (2016)

Novel targetable biomarkers in clear cell carcinoma of the breast uncovered by molecular profiling: A study of nine cases
por: Skenderi, Faruk, et al.
Publicado: (2020)

Comprehensive molecular profiling of advanced/metastatic olfactory neuroblastomas
por: Topcagic, Jasmina, et al.
Publicado: (2018)

Theranostic molecular profiling of pleomorphic ductal carcinoma of the breast
por: Vranic, Semir, et al.
Publicado: (2018)

Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling
por: Gargano, Stacey M., et al.
Publicado: (2019)

Precision medicine becomes reality—tumor type-agnostic therapy
por: Yan, Li, et al.
Publicado: (2018)

Comparison of the biomarkers for targeted therapies in primary extra‐mammary and mammary Paget's disease
por: Gatalica, Zoran, et al.
Publicado: (2020)

Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia
por: Arai, Hironori, et al.
Publicado: (2022)

A Positive Feedback Loop of ER-α36/EGFR Promotes Malignant Growth of ER-negative Breast Cancer Cells
por: Zhang, XianTian, et al.
Publicado: (2010)

Acinic cell carcinoma of the breast: A comprehensive review
por: Ajkunic, Azra, et al.
Publicado: (2022)

HER2-positive apocrine carcinoma of the breast: a population-based analysis of treatment and outcome
por: Skenderi, Faruk, et al.
Publicado: (2022)

Multiplatform molecular profiling identifies potentially targetable biomarkers in malignant phyllodes tumors of the breast
por: Gatalica, Zoran, et al.
Publicado: (2015)

TERT Gene Fusions Characterize a Subset of Metastatic Leydig Cell Tumors
por: Kruslin, Bozo, et al.
Publicado: (2021)

Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies
por: Willenbacher, Wolfgang, et al.
Publicado: (2018)

PD-L1 Status in Refractory Lymphomas
por: Vranic, Semir, et al.
Publicado: (2016)

Comprehensive genomic profiling of a metastatic small cell lung carcinoma with a complete and long-term response to atezolizumab: A case report
por: Tomic, Kresimir, et al.
Publicado: (2023)

RET-Altered Cancers—A Tumor-Agnostic Review of Biology, Diagnosis and Targeted Therapy Activity
por: Desilets, Antoine, et al.
Publicado: (2023)

Application of mTORC1 Inhibitors for Tissue-Agnostic Management of Standard-Therapy-Refractory Solid Tumors
por: Taghizadeh, Hossein, et al.
Publicado: (2022)

ALK fusions in the pan-cancer setting: another tumor-agnostic target?
por: Shreenivas, Aditya, et al.
Publicado: (2023)

The Bacillus Agnostic
Publicado: (1911)

TRK Inhibitors: Tissue-Agnostic Anti-Cancer Drugs
por: Han, Sun-Young
Publicado: (2021)

Hamartomas, teratomas and teratocarcinosarcomas of the head and neck: Report of 3 new cases with clinico-pathologic correlation, cytogenetic analysis, and review of the literature
por: Vranic, Semir, et al.
Publicado: (2008)

Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1
por: Joneja, Upasana, et al.
Publicado: (2017)

Agnostic Tendency in Doctors
Publicado: (1885)

Precision Oncology Comes of Age: Tumor-Agnostic Approaches
por: Lewis, Colleen, et al.
Publicado: (2020)

Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1
por: Gatalica, Zoran, et al.
Publicado: (2015)

The Role of BPTF in Melanoma Progression and in Response to BRAF-Targeted Therapy
por: Dar, Altaf A., et al.
Publicado: (2015)

Tumour-Agnostic Therapy for Pancreatic Cancer and Biliary Tract Cancer
por: Kato, Shunsuke
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ivu6pr2hs3h5ellsjpqludi99r